Statement of the Rehabilitation Medicine Society of Australia and New Zealand for the therapeutic use of botulinum toxin A in spasticity management
© 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians..
The Rehabilitation Medicine Society of Australia and New Zealand advocates the safe, effective and evidence-based use of botulinum toxin type A for spasticity management. The process requires appropriate training, alongside considerable knowledge and skills, to maximise efficacy. The processes before and after injection contribute to effectiveness. The gold standard of managing spasticity is for assessment by a multidisciplinary specialist team, deriving patient-centric goals, and designing an injection protocol to match these goals. The patient and/or carers are considered part of the decision-making team. Postinjection therapy and measurement of goal achievement are highly recommended as part of the wider holistic approach to management. The Society believes treatment failures can be minimised by following clear clinical guidelines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:54 |
|---|---|
| Enthalten in: |
Internal medicine journal - 54(2024), 1 vom: 24. Jan., Seite 178-182 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Anupam Datta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Botulinum Toxins, Type A |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 26.01.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1111/imj.16300 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367577992 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367577992 | ||
| 003 | DE-627 | ||
| 005 | 20240126232201.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240125s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/imj.16300 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM367577992 | ||
| 035 | |a (NLM)38267377 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gupta, Anupam Datta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Statement of the Rehabilitation Medicine Society of Australia and New Zealand for the therapeutic use of botulinum toxin A in spasticity management |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Internal Medicine Journal published by John Wiley & Sons Australia, Ltd on behalf of Royal Australasian College of Physicians. | ||
| 520 | |a The Rehabilitation Medicine Society of Australia and New Zealand advocates the safe, effective and evidence-based use of botulinum toxin type A for spasticity management. The process requires appropriate training, alongside considerable knowledge and skills, to maximise efficacy. The processes before and after injection contribute to effectiveness. The gold standard of managing spasticity is for assessment by a multidisciplinary specialist team, deriving patient-centric goals, and designing an injection protocol to match these goals. The patient and/or carers are considered part of the decision-making team. Postinjection therapy and measurement of goal achievement are highly recommended as part of the wider holistic approach to management. The Society believes treatment failures can be minimised by following clear clinical guidelines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a botulinum toxin | |
| 650 | 4 | |a goals | |
| 650 | 4 | |a spasticity | |
| 650 | 7 | |a Botulinum Toxins, Type A |2 NLM | |
| 650 | 7 | |a EC 3.4.24.69 |2 NLM | |
| 700 | 1 | |a Baguley, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Estell, John |e verfasserin |4 aut | |
| 700 | 1 | |a Geffon, Saul |e verfasserin |4 aut | |
| 700 | 1 | |a Goh, Kong |e verfasserin |4 aut | |
| 700 | 1 | |a Rawicki, Barry |e verfasserin |4 aut | |
| 700 | 1 | |a de Graaf, Stephen |e verfasserin |4 aut | |
| 700 | 1 | |a Olver, John |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Internal medicine journal |d 2001 |g 54(2024), 1 vom: 24. Jan., Seite 178-182 |w (DE-627)NLM113582811 |x 1445-5994 |7 nnns |
| 773 | 1 | 8 | |g volume:54 |g year:2024 |g number:1 |g day:24 |g month:01 |g pages:178-182 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/imj.16300 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 54 |j 2024 |e 1 |b 24 |c 01 |h 178-182 | ||